Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 15/20 | 0.43 |
| ▸ | MEN1 | O00255 | 10/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.43 |
| ▸ | HTT | P42858 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065376 | 1.00 | MAPT (0.43) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL7064483 | 0.85 | ERN1 (0.43) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL7064489 | 0.85 | ERN1 (0.43) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL7065379 | 0.83 | MAPT (0.42) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL7065857 | 0.83 | MAPT (0.54) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL7065853 | 0.83 | MAPT (0.54) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL7064448 | 0.82 | MAPT (0.42) | MAPTMEN1KMT2AALDH1A1HTT | |
| SCHEMBL7064443 | 0.82 | MAPT (0.42) | MAPTMEN1KMT2AALDH1A1HTT | |
| Water SCHEMBL7062207 | 0.81 | MAPT (0.41) | MAPTMEN1KMT2AALDH1A1HTT | |
| Water SCHEMBL7062205 | 0.81 | MAPT (0.41) | MAPTMEN1KMT2AALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313461-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | Melacure Therapeutics AB (SE) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002011715-A2 | THE USE OF BENZYLIDENEAMINOGUANIDINES AND HYDROXYGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS | MELACURE THERAPEUTICS AB (SE) | 2002-02-14 | — | — | WO | disclosed |